📰 Ellipses Pharma Ltd News
Ellipses Pharma Ltd News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ellipses Pharma Ltd. Real-time updates on events, politics, business and more.
March 30, 2023
More than 200 oncologists worldwide now involved in assessment and selection of potential treatments Ellipses Pharma ("Ellipses"), a global drug development company focused on accelerating the development
March 14, 2023
EP0042 is currently being investigated as a potential treatment option for patients with acute myeloid leukaemia Ellipses Pharma ("Ellipses"), a global drug development company focused on accelerating
February 1, 2023
IND approval allows for US trial sites and recruitment of eligible US patients to be added to EP0042's ongoing phase 1/2 trial Ellipses Pharma ("Ellipses"), a global drug development company focused
June 22, 2022
A phase 1/2 trial to initiate across a range of patient populations with RET-altered cancers Ellipses Pharma ("Ellipses"), a global drug development company focused on accelerating the development
May 25, 2022
Ellipses Pharma granted exclusive global rights to develop and commercialise SRB22, in solid tumours SunRock Biopharma S.L. ("SunRock"), a biopharmaceutical company that is developing a portfolio
May 25, 2022
Ellipses Pharma and SunRock Biopharma enter into a licensing agreement for a first-in-class bifunctional HER3:TRAIL fusion protein Ellipses Pharma granted exclusive global rights to develop and commercialise SRB22, in solid tumours LONDON and SANTIAGO DE COMPOSTELA, Spain, May 25, 2022: SunRock Biopharma S...